Adverse Event Management

Brain Cancer

Breast Cancer

Disparities in Cancer Care

Drug Safety

Colorectal Cancer

Liver Cancer

Gastric Cancers

Gastrointestinal Cancer

Genetics

Kidney Carcinoma

Bladder Cancer

Prostate Cancer

Genitourinary Cancer

Endometrial Cancer

Cervical Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Leukemia

Multiple Myeloma

Lymphoma

Hematology

Immuno-Oncology

Lung Cancer

Myeloproliferative Neoplasms

Nurse Navigation

Pediatric Cancer

Practice Management

Prevention

Radiation Oncology

Sarcomas

Melanoma

Skin Cancer

Supportive Care

Survivorship

Patients with early breast cancer may safely choose a shorter course of radiation therapy following reconstruction. 

Following Reconstruction, Patients With Early Breast Cancer May Safely Opt For a Shorter Course of Radiation Therapy

Patients who received pomalidomide, bortezomib, and dexamethasone achieved a median overall survival of 35.6 months compared with 31.6 months among patients treated with bortezomib and dexamethasone. 

PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma

Patients with EGFR-mutated non–small cell lung cancer had a median event-free survival of 30.8 months in the durvalumab arm and 19.6 months in the placebo arm.

Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC

Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease. 

Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups 

News

Latest News

FDA News

Survivorship 

Contributers

Media

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Oncology Drug Crash Course

Webinars

Cancer Summary Slides

Subscribe

Partners

Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

Articles

Elizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MagnetisMM-3 trial assessing elranatamab in multiple myeloma. 

Elizabeth Aronson Walks Through the Data Supporting Elranatamab Approval in Multiple Myeloma

Resistance training and walking can be beneficial for patients with multiple myeloma. 

Ambulation Improves Frailty Scores in Patients With Multiple Myeloma

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Quality Improvement

1rem

Authors

Nurses should be aware of patients who are at risk for immunotherapy-related myocarditis.

Immunotherapy-Related Myocarditis

Javid J. Moslehi, MD

Articles

Latest Conference Coverage